Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Applied Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $40 million initial public offering…
Bristol-Myers Squibb Company $19 Billion Senior Notes Offering
Davis Polk advised the representatives of the initial purchasers in connection with an unregistered offering of $19 billion…
Intercept Pharmaceuticals, Inc. Concurrent $231 Million Common Stock Offering and $230 Million Convertible Senior Notes Offering
Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 2,760…
NGM Biopharmaceuticals, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with an initial public offering of 7,521,394 shares of common stock of NGM…
Zai Lab Limited $230 Million Follow-On Offering of American Depositary Shares
Davis Polk advised Zai Lab Limited in connection with its follow-on offering of $230 million of American Depositary Shares…
Magenta Therapeutics, Inc. $64.8 Million Follow-On Offering of Common Stock
Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8…
TransMedics Group, Inc. Initial Public Offering
Davis Polk advised the representatives of the underwriters in connection with the $104.7 million initial public offering of…
Davis Polk Advises Pernix on Completing Sale of Substantially All of Its Assets to Currax Holdings LLC
Davis Polk advised Pernix Therapeutics Holdings, Inc. in connection with the sale of substantially all of its assets to…
Natera, Inc. $100 Million Follow-On Public Offering
Davis Polk advised the several underwriters in connection with the follow-on offering of 5,263,158 shares of common stock of…
Turning Point Therapeutics, Inc. Initial Public Offering
Davis Polk advised the representatives of the several underwriters in connection with a $191.5 million initial public…